Unusual variants of melanoma: fact or fiction?

Abstract:

:Evidence is reviewed separating unusual variants of melanoma from the large group of superficial spreading and nodular (SSM/NOD) histogenetic types. These include (1) the relationship of moles to melanoma of the SSM/ NOD types not found in melanoma arising in lentigo maligna (LMM), desmoplastic neurotrophic melanoma (DNM), mucosal lentiginous melanoma (MLM), or acral lentiginous melanoma (ALM); (2) the strong sunlight association in lentigo maligna (LM) and LMM not always present in SSM/NOD and not likely at all in acral or mucosal lesions (ALM, MLM); (3) epidemiological differences of age, race, and prognosis among the various subtypes; and (4) analogies to neoplasms in other organ systems. These data justify the following conclusions: (1) Variants of melanoma exist as in other neoplasms. (2) They are of epidemiological and therapeutic importance. (3) Until further data are available or networked, data base analysis should use microstage measurements in the common forms of SSM and NOD only, and approach the unusual variants separately and cautiously.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Sagebiel RW

subject

Has Abstract

pub_date

1996-12-01 00:00:00

pages

703-8

issue

6

eissn

0093-7754

issn

1532-8708

journal_volume

23

pub_type

杂志文章
  • Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer.

    abstract::The purpose of this pilot study was to determine the safety and feasibility of accelerated fractionation (via concomitant boost) radiotherapy (XRT) with concurrent carboplatin/paclitaxel chemotherapy for locally advanced stage III non-small cell lung carcinoma. Radiotherapy consisted of 3-dimensional conformal techniq...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/j.seminoncol.2005.03.004

    authors: Machtay M,Washam C,Devine P

    更新日期:2005-04-01 00:00:00

  • New serum markers of hepatocellular carcinoma.

    abstract::Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, usually develops in a liver already suffering from chronic damages, often cirrhosis. There has been marked progress in the treatment of HCC. However, effective treatments are limited to patients with less advanced HCC. The detection of HCC at an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.05.009

    authors: Masuzaki R,Karp SJ,Omata M

    更新日期:2012-08-01 00:00:00

  • Anemia and epoetin alfa in high-dose chemotherapy programs for breast cancer patients.

    abstract::Breast cancer patients undergoing therapeutic regimens of high-dose chemotherapy (HDCT) with circulating progenitor cell support often develop anemia. As a general consideration in the transplantation setting, red blood cell transfusions are normally required in patients who have passed the myeloablative phase after H...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.33529

    authors: Danova M,Ferrari S

    更新日期:2002-06-01 00:00:00

  • Preliminary experience with paclitaxel in advanced bladder cancer.

    abstract::In a phase II Eastern Cooperative Oncology Group trial, single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was administered to 26 patients with advanced urothelial cancer who had not received prior systemic chemotherapy. Paclitaxel was given at a dose of 250 mg/m2 by 24-hour continuous infusi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Roth BJ

    更新日期:1995-06-01 00:00:00

  • Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.

    abstract::Data from various phase I/II studies of carboplatin in combination with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) have suggested that the degree of thrombocytopenia seen is less than that expected when carboplatin is given alone. However, some studies also have suggested that the area under the p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Calvert AH,Boddy A,Bailey NP,Siddiqui N,Humphreys A,Hughes A,Robson L,Gumbrell L,Thomas H,Chapman F

    更新日期:1995-10-01 00:00:00

  • 3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.

    abstract::Early detection of response to neoadjuvant chemoradiation in esophageal cancer may allow individualization of treatment strategies and avoidance of unnecessary treatment. Although positron emission tomography (PET) with [(18)F]fluorodeoxyglucose (FDG) permits detection of changes in tumor proliferation before any chan...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.01.002

    authors: Chao KS

    更新日期:2007-04-01 00:00:00

  • The pathogenesis and clinical patterns of blastic crisis of chronic myeloid leukemia.

    abstract::Blast crisis terminates the life of the majority (approximately 80%) of patients with CML. The time of its onset appears to be a random phenomenon, varying from a probable coincidence occurrence with the onset of CML to more than a decade after onset of the chronic phase. In most patients the diagnosis is obvious as v...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Boggs DR

    更新日期:1976-09-01 00:00:00

  • Fatigue: definitions, mechanisms, and paradigms for study.

    abstract::Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalakas MC,Mock V,Hawkins MJ

    更新日期:1998-02-01 00:00:00

  • Secondary chemoprevention of upper aerodigestive tract tumors.

    abstract::Patients with successfully treated upper aerodigestive tract (UADT) tumors commonly develop second primary tumors (SPTs). These tumors occur more often than chance would predict, arise in both the upper or lower aerodigestive tracts, are frequently preceded by leukoplakia, and are a major cause of treatment-related fa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90048-x

    authors: Anderson WF,Hawk E,Berg CD

    更新日期:2001-02-01 00:00:00

  • Colon cancer in older adults.

    abstract::Colorectal cancer (CRC) is a common malignancy in the elderly. Randomized trials have demonstrated that adjuvant and palliative chemotherapy for CRC improves survival and quality of life. Unfortunately, there is a lack of evidence-based data about elderly patients to guide decisions regarding therapy. Clinical trials ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.08.004

    authors: Raftery L,Sanoff HK,Goldberg R

    更新日期:2008-12-01 00:00:00

  • The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis.

    abstract::Acquired immunodeficiency syndrome (AIDS)-related lymphomas consistently display a B-cell phenotype and are histogenetically related to germinal center (GC) or post-GC B cells in the overwhelming majority of cases. The pathogenesis of AIDS-related lymphoma is a multistep process involving factors provided by the host,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Gaidano G,Capello D,Carbone A

    更新日期:2000-08-01 00:00:00

  • Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.

    abstract::In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU re...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Van Cutsem E,Blijham GH

    更新日期:1999-02-01 00:00:00

  • Overview of phase I trials of multitargeted antifolate (MTA, LY231514).

    abstract::Multitargeted antifolate (MTA, LY231514) is a novel antifolate antimetabolite, with antitumor activity via inhibition of thymidylate synthase, glycinamide formyl transferase, and dihydrofolate reductase. Three dosing schedules have been investigated in the phase I setting: daily x5 every 21 days, weekly x4 every 42 da...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rinaldi DA

    更新日期:1999-04-01 00:00:00

  • Pathological and molecular assessment of sentinel lymph nodes in solid tumors.

    abstract::Sentinel nodes (SNs) are the first set of nodes to receive drainage and cancer cells from a primary tumor. While there may be a single SN, frequently there are one to three or more SNs. The development of sentinel node surgery over the last decade has led to dramatic changes in the surgical approach to regional nodes ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.32894

    authors: Krag DN,Weaver DL

    更新日期:2002-06-01 00:00:00

  • Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.

    abstract::Over 50% of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have stage IV disease at presentation and the most likely organ to be affected by metastases is the liver. Hepatic involvement and hepatic tumor burden is a key prognostic factor affecting survival of these patients and 80% eventually di...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.07.002

    authors: Keutgen XM,Schadde E,Pommier RF,Halfdanarson TR,Howe JR,Kebebew E

    更新日期:2018-08-01 00:00:00

  • Docetaxel and exisulind in hormone-refractory prostate cancer.

    abstract::Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0093-7754(01)90156-3

    authors: Ryan CW,Stadler WM,Vogelzang NJ

    更新日期:2001-08-01 00:00:00

  • Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.

    abstract::A phase II study was conducted to evaluate the efficacy and toxicity of lomustine, cytarabine, mitoxantrone and prednisone (CAMP) chemotherapy in doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphomas (NHL). Among 30 patients, the complete remission rate was 27% (duration: 10, 16, 22, 35,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Ruit JB,Löwenberg B,Hagenbeek A,Verhoef GE,Wielenga JJ,Michiels J,Sizoo W

    更新日期:1990-12-01 00:00:00

  • Pharmacogenetics in esophageal cancer.

    abstract::The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics. This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.04.031

    authors: Wu X,Lu C,Chiang SS,Ajani JA

    更新日期:2005-12-01 00:00:00

  • Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.

    abstract::Elderly patients with malignant gliomas present unique treatment challenges. Data are limited on the efficacy of various treatment modalities for high-grade gliomas in the elderly patient population, particularly for patients over 70 years of age, and the most appropriate treatment strategies remain a matter of debate...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.027

    authors: Chinot OL

    更新日期:2003-12-01 00:00:00

  • Etoposide plus ifosfamide plus cisplatin in the treatment of small cell lung cancer.

    abstract::Approximately 25% of all lung cancer cases diagnosed in 1993 were due to small cell lung cancer (SCLC). Approximately one third of all SCLC patients present with limited disease. Efforts to improve treatment results for patients with limited-stage SCLC include two recent meta-analyses of combined-modality treatment in...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sandler AB

    更新日期:1998-02-01 00:00:00

  • Descriptive epidemiology and risk factors for head and neck cancer.

    abstract::Although more common in developing countries, over 11,000 deaths will occur in the United States from head and neck cancer in 2004. Squamous cell carcinomas account for the vast majority of cases in the United States and the majority of these are related to exposure to tobacco and alcohol. Newer data suggest a genetic...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.013

    authors: Sturgis EM,Wei Q,Spitz MR

    更新日期:2004-12-01 00:00:00

  • Practical considerations in the evaluation and management of adrenocortical cancer.

    abstract::Adrenocortical cancer (ACC) is a rare, challenging disease with a broad range of clinical presentations. Often presenting in an advanced stage with a large, locally invasive primary tumor or with Cushing's syndrome, it requires a multidisciplinary approach to treatment. We discuss controversies in the evaluation and m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.10.011

    authors: Balasubramaniam S,Fojo T

    更新日期:2010-12-01 00:00:00

  • Third-line salvage chemotherapy in Hodgkin's disease.

    abstract::CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible. ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Bonadonna G,Viviani S,Valagussa P,Bonfante V,Santoro A

    更新日期:1985-03-01 00:00:00

  • VP-16 and cisplatin in the treatment of non-small-cell lung cancer.

    abstract::The EORTC Lung Cancer Working Party investigated the effects of combination therapy with VP-16 (Ve-Pesid) and cisplatin in the treatment of non-small-cell lung cancer (NSCLC). Neither agent alone is recognized as being associated with a high rate of response in NSCLC, but the combination proved beneficial in our hands...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Klastersky J

    更新日期:1985-03-01 00:00:00

  • Carcinoembryonic antigen-based vaccines.

    abstract::Carcinoembryonic antigen (CEA) is a glycoprotein that is normally expressed in certain parts of the body and commonly overexpressed in most carcinomas of the colon, rectum, breast, lung, pancreas, and gastrointestinal tract. Increased expression of CEA promotes increased intercellular adhesions, which may lead to meta...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00233-1

    authors: Marshall J

    更新日期:2003-06-01 00:00:00

  • Therapy of superficial bladder cancer.

    abstract::Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (Ie, Ta, Tl, and carcinoma in situ [CIS]) with specific objectives that include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression, and prolonging s...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Nseyo UO,Lamm DL

    更新日期:1996-10-01 00:00:00

  • Toxicity patterns with immunomodulating antibodies and their combinations.

    abstract::Immune checkpoint molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), but also LAG-3 and TIM-3, are involved in regulation of peripheral tolerance in order to prevent autoimmunity. Blocking of these cell surface proteins by antibodies has resulted in remarkable anti-tumor immunity; howev...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.02.011

    authors: Haanen JB,Thienen Hv,Blank CU

    更新日期:2015-06-01 00:00:00

  • Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

    abstract::The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally effective. However, the carboplatin/etoposide regimen caused significantly less nausea, vomiting, n...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Kosmidis PA,Samantas E,Fountzilas G,Pavlidis N,Apostolopoulou F,Skarlos D

    更新日期:1994-06-01 00:00:00

  • Management of borderline tumors of the ovary: state of the art.

    abstract::Evidence published during several decades has shown that there is a group of epithelial ovarian tumors having histological and biological features between those of clearly benign and frankly malignant tumors. In 1963, FIGO accepted an intermediate group of ovarian carcinomas of low malignant potential. In 1973, WHO ad...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Tropé C,Kaern J

    更新日期:1998-06-01 00:00:00

  • Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors.

    abstract::Improving local tumor control is a goal of modern radiotherapy that will directly impact a majority of cancer patients. Numerous attempts to develop radiosensitizing agents have, however, met with limited clinical success. Recent advances in gene therapeutic approaches have allowed researchers to combine gene therapy ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Advani SJ,Chmura SJ,Weichselbaum RR

    更新日期:1997-12-01 00:00:00